Quantification of Respirable Aerosol Particles from Speech and Language Therapy Exercises.

Respirable aerosols—Speech language pathology—Voice therapy—Respiratory pathogens—SARS-CoV-2

Journal

Journal of voice : official journal of the Voice Foundation
ISSN: 1873-4588
Titre abrégé: J Voice
Pays: United States
ID NLM: 8712262

Informations de publication

Date de publication:
25 Aug 2022
Historique:
received: 21 04 2022
revised: 05 07 2022
accepted: 06 07 2022
entrez: 28 8 2022
pubmed: 29 8 2022
medline: 29 8 2022
Statut: aheadofprint

Résumé

Voice assessment and treatment involve the manipulation of all the subsystems of voice production, and may lead to production of respirable aerosol particles that pose a greater risk of potential viral transmission via inhalation of respirable pathogens (eg, SARS-CoV-2) than quiet breathing or conversational speech. To characterise the production of respirable aerosol particles during a selection of voice assessment therapy tasks. We recruited 23 healthy adult participants (12 males, 11 females), 11 of whom were speech-language pathologists specialising in voice disorders. We used an aerodynamic and an optical particle sizer to measure the number concentration and particle size distributions of respirable aerosols generated during a variety of voice assessment and therapy tasks. The measurements were carried out in a laminar flow operating theatre, with a near-zero background aerosol concentration, allowing us to quantify the number concentration and size distributions of respirable aerosol particles produced from assessment/therapy tasks studied. Aerosol number concentrations generated while performing assessment/therapy tasks were log-normally distributed among individuals with no significant differences between professionals (speech-language pathologists) and non-professionals or between males and females. Activities produced up to 32 times the aerosol number concentration of breathing and 24 times that of speech at 70-80 dBA. In terms of aerosol mass, activities produced up to 163 times the mass concentration of breathing and up to 36 times the mass concentration of speech. Voicing was a significant factor in aerosol production; aerosol number/mass concentrations generated during the voiced activities were 1.1-5 times higher than their unvoiced counterpart activities. Additionally, voiced activities produced bigger respirable aerosol particles than their unvoiced variants except the trills. Humming generated higher aerosol concentrations than sustained /a/, fricatives, speaking (70-80 dBA), and breathing. Oscillatory semi-occluded vocal tract exercises (SOVTEs) generated higher aerosol number/mass concentrations than the activities without oscillation. Water resistance therapy (WRT) generated the most aerosol of all activities, ∼10 times higher than speaking at 70-80 dBA and >30 times higher than breathing. All activities generated more aerosol than breathing, although a sizeable minority were no different to speaking. Larger number concentrations and larger particle sizes appear to be generated by activities with higher suspected airflows, with the greatest involving intraoral pressure oscillation and/or an oscillating oral articulation (WRT or trilling).

Identifiants

pubmed: 36031505
pii: S0892-1997(22)00207-7
doi: 10.1016/j.jvoice.2022.07.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Competing interests The authors declare no competing interests.

Auteurs

Brian Saccente-Kennedy (B)

Department of Speech and Language Therapy (ENT), Royal National Ear, Nose and Throat and Eastman Dental Hospitals, University College London Hospitals NHS Foundation Trust, London, United Kingdom.

Justice Archer (J)

School of Chemistry, University of Bristol, Bristol, United Kingdom.

Henry E Symons (HE)

School of Chemistry, University of Bristol, Bristol, United Kingdom.

Natalie A Watson (NA)

Department of Ear, Nose and Throat Surgery, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Christopher M Orton (CM)

Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom; Department of Respiratory Medicine, Chelsea & Westminster Hospital, London, United Kingdom; National Heart and Lung Institute, Guy Scadding Building, Imperial College London, London, United Kingdom.

William J Browne (WJ)

School of Education, University of Bristol, Bristol, United Kingdom.

Joshua Harrison (J)

School of Chemistry, University of Bristol, Bristol, United Kingdom.

James D Calder (JD)

Department of Bioengineering, Imperial College London, United Kingdom; Fortius Clinic, London, United Kingdom.

Pallav L Shah (PL)

Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom; Department of Respiratory Medicine, Chelsea & Westminster Hospital, London, United Kingdom; National Heart and Lung Institute, Guy Scadding Building, Imperial College London, London, United Kingdom.

Declan Costello (D)

Ear, Nose and Throat Department, Wexham Park Hospital, Slough, United Kingdom.

Jonathan P Reid (JP)

School of Chemistry, University of Bristol, Bristol, United Kingdom.

Bryan R Bzdek (BR)

School of Chemistry, University of Bristol, Bristol, United Kingdom. Electronic address: b.bzdek@bristol.ac.uk.

Ruth Epstein (R)

Department of Speech and Language Therapy (ENT), Royal National Ear, Nose and Throat and Eastman Dental Hospitals, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: ruth.epstein@nhs.net.

Classifications MeSH